Institutions & recognition

Every designation can be checked in its register.

  • EMA · 2006European Medicines Agency · Orphan designation for Retriacyl.
  • FDA · 2014U.S. Food and Drug Administration · Orphan Drug Designation for Retriacyl (May 21, 2014). Retriacyl is not approved by the FDA.
  • FDACelavista Mito‑Biogenesis is an FDA‑registered facility (FEI 3027397746).
  • ASEBIOCelavista Mito‑Biogenesis is a member of the Spanish Bioindustry Association (Biomedical area).
  • PARTNERSScientific partners: CSIC‑INMA and the University of Navarra (Naturemimetix).